Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2025-12-31 @ 2:57 PM
Study NCT ID:
NCT00707135
Status:
COMPLETED
Last Update Posted:
2014-01-17
First Post:
2008-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rapamycin in Advanced Cancers
Sponsor:
University of Chicago
Organization:
Study Overview
Official Title:
A Phase Ib Study of Rapamycin (Sirolimus) in Patients With Advanced Malignancies
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: